Politico reports Trump pledged that low-income Americans in states joining his government–drugmaker direct-negotiation plan would quickly gain Medicaid access to costly GLP-1 obesity drugs such as Wegovy and Zepbound. Nine months on, access has narrowed: only Indiana has publicly backed the plan; several states have stopped reimbursing these drugs for Medicaid patients and others are considering ending coverage. Most states interviewed say they will not participate, citing budget pressure and co

Politico reports Trump pledged that low-income Americans in states joining his government–drugmaker direct-negotiation plan would quickly gain Medicaid access to costly GLP-1 obesity drugs such as Wegovy and Zepbound. Nine months on, access has narrowed: only Indiana has publicly backed the plan; several states have stopped reimbursing these drugs for Medicaid patients and others are considering ending coverage. Most states interviewed say they will not participate, citing budget pressure and concerns about the long-term fiscal sustainability of the model, and report other states’ GLP-1 spending has exceeded expectations by several hundred million dollars.